Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Shorting stocks: Broken stocks - Analysis -- Ignore unavailable to you. Want to Upgrade?

To: Q. who wrote (805)	12/20/1997 10:06:00 PM
From: Mike Harkness	Respond to of 2506

John, I covered that one on Friday at 29 3/8. It wasn't acting weak enough for me. I agree the long term prospects look good. I was just shorting it as a trade. Good Luck Mike

To: Q. who wrote (805)	12/21/1997 12:29:00 AM
From: patchman	Respond to of 2506

John, do you also like SFAM at these levels?

To: Q. who wrote (805)	12/23/1997 8:29:00 AM
From: Dale Baker	Read Replies (1) \| Respond to of 2506

John, look at SODK and let me know what you think. Looks like a sea of troubles for them. Could vanish under 5 soon.

To: Q. who wrote (805)	12/24/1997 9:38:00 AM
From: Dale Baker	Respond to of 2506

John, some MEDA news: 08:51 ET Medaphis Corp (MEDA) 6 15/32: Health care information services company says results for FY95 and FY96 and for the first nine months of '97 will be restated to account for the Dec. '95 acquisition of Medical Management Sciences as a purchase accounting transaction instead of a pooling-of-interests.

To: Q. who wrote (805)	1/5/1998 1:49:00 AM
From: Mama Bear	Read Replies (1) \| Respond to of 2506

Have you looked at ESMC? It recently did a 1:4 reverse split, and annonced a heinous convertible after the bell Friday. KILLMAN, N.J., Jan. 2 /PRNewswire/ -- Escalon Medical Corp. (Nasdaq: ESMC) today announced the completion of a private placement of $1.35 million of Series A 6% Convertible Preferred Stock. Commenting on the transaction, Richard J. DePiano, the Company's Chairman and Chief Executive Officer, said, "This private placement will provide Escalon with the necessary working capital and financial flexibility to continue to fund our exciting drug delivery and pharmaceutical products business." Escalon Medical received funds totaling approximately $1,158,000, net of offering costs of $192,000. After March 1, 1998, the preferred stock may be converted at the option of the holder into shares of common stock at a rate to be determined by dividing the liquidation value by the conversion price then in effect. The conversion price will be the lesser of the five-day average closing bid price prior to December 31, 1997 or up to 82% of the five-day average closing bid price prior to the conversion date. Any preferred stock that is outstanding on December 31, 1999 will be automatically converted into common stock. In connection with the issuance of the preferred stock, the Company issued five-year warrants to purchase 90,000 shares of common stock to the buyer and placement agent, at exercise prices ranging from the closing bid price as of December 31, 1997 to 135% of that closing bid price. The Company also announced that effective January 1, 1998, it will relocate its headquarters from Skillman, N.J. to 351 East Conestoga Road, Wayne, Pa. 19087. The new telephone number for Escalon Medical will be 610-688-6830. Founded in 1987, Escalon develops, markets and distributes ophthalmic medical devices and pharmaceuticals and is developing its ophthalmic drug delivery system. In addition to its new headquarters in Wayne, Pennsylvania, Escalon has manufacturing operations near Milwaukee, Wisconsin. Note: This news release contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those projected or forecasted. Forward-looking statements include certain information relating to the Company's plans to (i) develop its surgical and pharmaceutical products business; (ii) enter into a joint venture agreement concerning its intellectual laser properties; (iii) file an IND with the FDA regarding diclofenac; as well as other statements contained herein that are preceded by, followed by or include the words "believe," "expects," "anticipates," or expressions of similar import. For such statements, the Company claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Such risks and uncertainties include, but are not limited to, those disclosed in the Company's Form 10-K for fiscal year 1997, which has been filed with the Securities and Exchange Commission. To receive additional information on Escalon Medical Corp., via fax, at no charge, dial 1-800-PRO-INFO and enter code ESMC. SOURCE Escalon Medical Corp. CO: Escalon Medical Corp. ST: New Jersey, Pennsylvania IN: MTC SU: 01/02/98 16:51 EST prnewswire.com Barb